Galectin Therapeutics Inc
GALT
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
9
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
$10 billion private placement to Berkshire Hathaway as part of equity raise.
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar launches research coverage of SpaceX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.20 | 3.10 | -0.03% |
| CAC 40 | 8,191.64 | 17.45 | -0.21% |
| DAX 40 | 24,918.22 | 205.95 | -0.82% |
| Dow JONES (US) | 51,307.79 | 228.91 | 0.45% |
| FTSE 100 | 10,347.85 | 25.66 | -0.25% |
| HKSE | 25,633.21 | 405.11 | -1.56% |
| NASDAQ | 27,093.90 | 7.09 | 0.03% |
| Nikkei 225 | 68,402.13 | 1,667.89 | 2.50% |
| NZX 50 Index | 13,115.08 | 55.63 | -0.42% |
| S&P 500 | 7,609.78 | 9.82 | 0.13% |
| S&P/ASX 200 | 8,785.70 | 5.90 | 0.07% |
| SSE Composite Index | 4,083.97 | 8.87 | 0.22% |